---
document_datetime: 2025-10-22 09:00:16
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tezspire-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tezspire-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.3631585
conversion_datetime: 2025-12-14 12:37:09.070593
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## TEZSPIRE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                              |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 18/09/2025                          | 20/10/2025                                  | SmPC, Annex                      | Please refer to Scientific Discussion 'Tezspire-H-C- |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000245013                     | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Tezspire, based on results from study WAYPOINT (D5242C00001); this is a global, multicentre, randomised, double- blind, parallel-group, placebo-controlled study that evaluated the efficacy and safety of tezepelumab compared with placebo in the treatment of CRSwNP. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The updated RMP version 6.2 is acceptable. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes and to update the PI and the Package Leaflet in accordance with the   |            |     | II and PL   | 5588-II- EMAVR0000245013'   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------|
| Variation type IB / EMA/VR/0000284900 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/08/2025 | N/A |             |                             |

<div style=\"page-break-after: always\"></div>

|                                       | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted   |            |            |    |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| Variation type IB / EMA/VR/0000269627 | This was an application for a group of variations. B.II.b.2 Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/07/2025 | 20/10/2025 | PL |

<div style=\"page-break-after: always\"></div>

|                                       | arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted B.II.e.6 Change in any part of the (primary) packaging material not in contact with the finished product formulation (such as colour of flip-off caps, colour code rings on ampoules, change of needle shield (different plastic used)) - B.II.e.6.a Change that affects the product information - Accepted   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000262075 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Submission of additional clinical and non-clinical studies, including BE-studies. - Accepted Submission of the final report from study D5180C00021 listed as a category 3 study in the RMP. This is a regional, multicentre, randomised, double-blind, placebo controlled, parallel group, phase 3 study to evaluate the efficacy and safety of tezepelumab in adults with severe                                                                                                                                                                                                               | 10/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | uncontrolled asthma (DIRECTION). The submitted RMP version 5.2 is acceptable.                                                                                                                                                  |            |     |             |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000275188 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted                  | 26/06/2025 | N/A |             |
| Variation type IB / EMA/VR/0000253536 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted | 19/03/2025 | N/A |             |
| PSUR / EMA/PSUR/0000257896            | - -                                                                                                                                                                                                                            |            |     | Maintenance |